Patient characteristics and amount of treatment received for HL
| . | Patients with t-AML/MDS (n = 106) . | All patients (n = 11 952) . |
|---|---|---|
| Sex | ||
| Male | 53% | 56% |
| Age | ||
| Median (range) | 43 (16-71) | 34 (16-75) |
| HL risk group | ||
| Early favorable | 5% | 25% |
| Early unfavorable | 20% | 34% |
| Advanced | 75% | 41% |
| First-line chemotherapy for HL | ||
| No BEACOPP | 23% | 49% |
| <4 cycles BEACOPPescalated | 19% | 23% |
| ≥4 cycles BEACOPPescalated | 58% | 28% |
| Radiotherapy for HL | ||
| No RT | 45% | 27% |
| <EF | 41% | 63% |
| EF | 14% | 10% |
| . | Patients with t-AML/MDS (n = 106) . | All patients (n = 11 952) . |
|---|---|---|
| Sex | ||
| Male | 53% | 56% |
| Age | ||
| Median (range) | 43 (16-71) | 34 (16-75) |
| HL risk group | ||
| Early favorable | 5% | 25% |
| Early unfavorable | 20% | 34% |
| Advanced | 75% | 41% |
| First-line chemotherapy for HL | ||
| No BEACOPP | 23% | 49% |
| <4 cycles BEACOPPescalated | 19% | 23% |
| ≥4 cycles BEACOPPescalated | 58% | 28% |
| Radiotherapy for HL | ||
| No RT | 45% | 27% |
| <EF | 41% | 63% |
| EF | 14% | 10% |